Magic-mushroom drug lifts depression in first human trial
Magic mushrooms are taken for their psychedelic effects, but end up improving depression treatment.
A hallucinogenic drug derived from magic mushrooms could be useful in treating depression, the first safety study of this approach has concluded.
Researchers from Imperial College London gave 12 people psilocybin, the active component in magic mushrooms. All had been clinically depressed for a significant amount of time — on average 17.8 years. None of the patients had responded to standard medications, such as selective serotonin re-uptake inhibitors (SSRIs), or had electroconvulsive therapy.
Brain scans reveal how LSD affects consciousness
One week after receiving an oral dose of psilocybin, all patients experienced a marked improvement in their symptoms. Three months on, five patients were in complete remission.